Literature DB >> 11322275

HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.

D M Burger1, C A Boucher, P L Meenhorst, C L Kraayeveld, P Portegies, J W Mulder, R M Hoetelmans, J H Beijnen.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) RNA can be detected in the cerebrospinal fluid (CSF) of 75-90% of all HIV-infected patients. However, it is not yet known which factors influence the amount of HIV-1 in the CSF, either qualitatively or quantitatively. We have analysed HIV-1 RNA in CSF samples from 24 HIV-infected patients using zidovudine who underwent lumbar puncture in order to establish a diagnosis for a neurological disorder. Several factors were examined for possible correlation with the amount of HIV-1 RNA in the CSF: age, gender, the medical indication for lumbar puncture, the most recent CD4 cell count in blood, zidovudine dose, duration of treatment with zidovudine, the zidovudine concentration in plasma and CSF, and the total protein concentration in plasma and CSF. The only statistically significant factor was the total protein level in the CSF, which showed a positive relation with the amount of HIV-1 RNA in the CSF. This study indicates that increased levels of HIV-1 RNA in the CSF of neurologically symptomatic patients are the result of damage to the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 11322275

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis.

Authors:  Georgette D Kanmogne; Kathy Schall; Jessica Leibhart; Bryan Knipe; Howard E Gendelman; Yuri Persidsky
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-10       Impact factor: 6.200

Review 2.  Cocaine and HIV-1 interplay: molecular mechanisms of action and addiction.

Authors:  Shilpa Buch; Honghong Yao; Minglei Guo; Tomohisa Mori; Tsung-Ping Su; John Wang
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-16       Impact factor: 4.147

3.  Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: role of CCR5 and implications for viral neuropathogenesis.

Authors:  Bo Yang; Sangya Singh; Rafael Bressani; Georgette D Kanmogne
Journal:  J Neurosci Res       Date:  2010-11-01       Impact factor: 4.164

4.  Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.

Authors:  A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-08       Impact factor: 4.147

5.  STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier.

Authors:  Anathbandhu Chaudhuri; Bo Yang; Howard E Gendelman; Yuri Persidsky; Georgette D Kanmogne
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

6.  Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia.

Authors:  Malcolm J Avison; Avindra Nath; Robin Greene-Avison; Frederick A Schmitt; Rodney A Bales; As'ad Ethisham; Richard N Greenberg; Joseph R Berger
Journal:  J Neurovirol       Date:  2004-08       Impact factor: 2.643

7.  HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling.

Authors:  Bo Yang; Sidra Akhter; Anathbandhu Chaudhuri; Georgette D Kanmogne
Journal:  Microvasc Res       Date:  2008-11-28       Impact factor: 3.514

8.  Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.

Authors:  Paulo P Christo; Dirceu B Greco; Agdemir W Aleixo; Jose A Livramento
Journal:  BMC Infect Dis       Date:  2007-12-21       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.